BACKGROUND: It is speculated that different localizations of lymphoproliferative disorder after solid organ transplantation (PTLD) have different features and represent specific behavior as well as prognostic individualities. OBJECTIVES: To compare characteristics of hepatic PTLD (H-PTLD) with non-hepatic PTLD (NH-PTLD) in liver transplant recipients. MATERIALS AND METHODS: We searched PubMed and Google Scholar for all published reports of PTLD in liver recipients within their liver. Reported characteristics of H-PTLD and NH-PTLD were compared. RESULTS: A total of 21 studies from various countries were found. Overall, 169 liver recipients with PTLD were included in the analysis, of whom 83 (49%) had H-PTLD. Patients with H-PTLD were more likely to test positive for Epstein-Barr virus (EBV) (p < 0.0001), be older at the time of transplantation (p = 0.009), have a shorter time to PTLD development (80 vs. 41% early-onset PTLD; p < 0.001), and have bone marrow involvement (p = 0.03). Multivariate linear regression showed that H-PTLD and EBV positivity, but not age at transplant, were independently associated with time to PTLD development (p = 0.003, p < 0.0001, and p = 1.0, respectively). CONCLUSIONS: Liver transplant patients exhibiting early deterioration of graft function or other hepatic symptoms should, in addition to assessment for rejection, be evaluated for H-PTLD. In addition, all H-PTLD patients should be evaluated for bone marrow involvement, especially if they are EBV positive. Prospective studies with large patient populations are needed to confirm our results.
BACKGROUND: It is speculated that different localizations of lymphoproliferative disorder after solid organ transplantation (PTLD) have different features and represent specific behavior as well as prognostic individualities. OBJECTIVES: To compare characteristics of hepatic PTLD (H-PTLD) with non-hepatic PTLD (NH-PTLD) in liver transplant recipients. MATERIALS AND METHODS: We searched PubMed and Google Scholar for all published reports of PTLD in liver recipients within their liver. Reported characteristics of H-PTLD and NH-PTLD were compared. RESULTS: A total of 21 studies from various countries were found. Overall, 169 liver recipients with PTLD were included in the analysis, of whom 83 (49%) had H-PTLD. Patients with H-PTLD were more likely to test positive for Epstein-Barr virus (EBV) (p < 0.0001), be older at the time of transplantation (p = 0.009), have a shorter time to PTLD development (80 vs. 41% early-onset PTLD; p < 0.001), and have bone marrow involvement (p = 0.03). Multivariate linear regression showed that H-PTLD and EBV positivity, but not age at transplant, were independently associated with time to PTLD development (p = 0.003, p < 0.0001, and p = 1.0, respectively). CONCLUSIONS: Liver transplant patients exhibiting early deterioration of graft function or other hepatic symptoms should, in addition to assessment for rejection, be evaluated for H-PTLD. In addition, all H-PTLDpatients should be evaluated for bone marrow involvement, especially if they are EBV positive. Prospective studies with large patient populations are needed to confirm our results.
Authors: A O Stieber; O Boillot; C Scotti-Foglieni; M A Nalesnik; R D Gordon; I Marino; V Mazzaferro; T E Starzl Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066
Authors: J D Nuckols; P W Baron; T T Stenzel; B A Olatidoye; J E Tuttle-Newhall; P A Clavien; D N Howell Journal: Am J Surg Pathol Date: 2000-05 Impact factor: 6.394
Authors: M Levy; L Backman; B Husberg; R Goldstein; R McMillan; J Gibbs; T A Gonwa; M Holman; G Klintmalm Journal: Transplant Proc Date: 1993-02 Impact factor: 1.066
Authors: D W Hanto; G Frizzera; K J Gajl-Peczalska; K Sakamoto; D T Purtilo; H H Balfour; R L Simmons; J S Najarian Journal: N Engl J Med Date: 1982-04-15 Impact factor: 91.245
Authors: Miroslav Djokic; Michelle M Le Beau; Lode J Swinnen; Sonali M Smith; Charles M Rubin; John Anastasi; Katrin M Carlson Journal: Genes Chromosomes Cancer Date: 2006-03 Impact factor: 5.006